A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Public ClinicalTrials.gov record NCT00100984. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.
Study identification
- NCT ID
- NCT00100984
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 8 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 20, 2004
- Primary completion
- Jul 15, 2005
- Completion
- Jul 15, 2005
- Last update posted
- Jun 19, 2017
2004 – 2005
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Hobson City | Alabama | 36201 | — |
| Not listed | Los Angeles | California | 90033 | — |
| Not listed | Los Angeles | California | 90036 | — |
| Not listed | Washington D.C. | District of Columbia | 20007 | — |
| Not listed | Washington D.C. | District of Columbia | 20009 | — |
| Not listed | Orlando | Florida | 32803 | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Macon | Georgia | 31201 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Chicago | Illinois | 60657 | — |
| Not listed | Baltimore | Maryland | 21201 | — |
| Not listed | Boston | Massachusetts | 02215-3318 | — |
| Not listed | Jackson | Mississippi | 39216-4505 | — |
| Not listed | St Louis | Missouri | 63139 | — |
| Not listed | Newark | New Jersey | 07103 | — |
| Not listed | New York | New York | 10011 | — |
| Not listed | New York | New York | 10016 | — |
| Not listed | Huntersville | North Carolina | 28078 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Houston | Texas | 77004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00100984, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 19, 2017 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00100984 live on ClinicalTrials.gov.